

**LONDON  
STOCK  
EXCHANGE**

An LSEG Business

NS    Miscellaneous

## APPOINTMENT OF KATHERINE FLEMING TO ADVISORY BOARD

### [HELLENIC DYNAMICS PLC](#)

Released 07:00:05 27 March 2023

RNS Number : 2334U  
Hellenic Dynamics PLC  
27 March 2023

27 March 2023

**Hellenic Dynamics plc**  
**(*"Hellenic Dynamics" or the "Company"*)**

### **Appointment of Katherine Fleming to Advisory Board**

London, 27 March 2023: Hellenic Dynamics plc (LSE: HELD) a medical cannabis cultivation company, is pleased to announce the appointment of Katherine Fleming to its Advisory Board. Katherine is currently the President and CEO of the J. Paul Getty Trust, the international cultural and philanthropic institution, overseeing its 1,500 employees and US\$8.5 billion endowment fund.

Katherine previously held the position of Provost and Professor of History of New York University, the largest private university in the United States by enrolment, where she is also the Alexander S. Onassis Chair of Hellenic Studies. As Provost, she oversaw the University's global academic strategy and was responsible for budgetary allocation. Past international appointments have included serving as President of the Board of the University of Piraeus, Greece and as associate member of the faculty of the École Normale Supérieure in Paris, France.

Katherine holds a number of honours including being named to the French Légion d'Honneur and being decorated by the Greek Government as a commander in the Order of Beneficence. In 2016 Katherine was recognized for her contributions to Greek culture by being granted honorary Greek citizenship.

Katherine will assist Hellenic Dynamics both domestically in Greece with her strong and well-established relationships, as well as on the international stage as it aims to be the dominant supplier of THC medical cannabis products in Europe.

Hellenic Dynamics is a medical cannabis cultivator specifically focused on the cultivation and supply of tetrahydrocannabinol ("THC") dominant strains of medical cannabis flowers destined for the rapidly growing medical cannabis markets across Europe. In December 2022, Hellenic Dynamics became the first medical cannabis cultivator to list on the London Stock Exchange's main market for listed securities.

#### **Davinder Rai, CEO of Hellenic Dynamics, commented:**

*"We are honoured to have Katherine join our Advisory Board and I personally look forward to working with her. Katherine brings a huge breadth of experience that will benefit Hellenic both domestically in Greece and in wider Europe."*

#### **Katherine Fleming, commented:**

*"I'm delighted to join Hellenic Dynamics, which connects two worlds about which I care deeply: patients for whom medical cannabis can improve their quality of life and outcomes, and Greece - a country with massive potential for being the leader in the European medical cannabis cultivation space."*

**Enquires:**

Hellenic Dynamics plc	+44 (0)20 3818 7850
Davinder Rai	davinder@hellenicdynamics.com

Cairn Financial Advisers LLP	
Emily Staples / Jo Turner	+44 (0)20 7213 0880

Peterhouse Capital	
Lucy Williams / Charles Goodfellow	+44 (0)20 7469 0930

J&H Communications	
George Hudson	+44 (0)7803 603130

**About Hellenic Dynamics plc**

Founded in 2019, Hellenic Dynamics is specifically focused on the cultivation and supply of THC ("tetrahydrocannabinol") - dominant strains of medical cannabis flowers, destined for the growing medical cannabis markets across Europe. Hellenic Dynamics' core strategy is to develop and operate its 40,000 square metre active cultivation licence from its 195,506 square metre facility located near Thessaloniki in Northern Greece. In full production, Hellenic Dynamics is capable of producing over 54,000 kg of dried flowers per annum.

Hellenic Dynamics will take advantage of its relatively low cost base resulting from a comparatively low cost of power, having its own running water supply and the labour rates for skilled and semi-skilled labour in Northern Greece.

25 European countries now allow medical cannabis via prescription and the European cannabis market is expected to reach €43.3 billion per annum by 2027. Sales of Hellenic Dynamics' dried THC-dominant cannabis flowers and extracts are initially intended for export into Europe's largest market - Germany, in addition to other European markets including domestically in Greece.

As the first medical cannabis cultivator to obtain a listing on the main market for listed securities of the London Stock Exchange, Hellenic is significantly different to the number of CBD (Cannabidiol) related companies that have appeared over the recent years. Hellenic Dynamics cultivates THC-dominant medical cannabis flowers. THC-dominant medical cannabis products are only available via a medical prescription. Medicinal cannabis has been approved for use both in the United Kingdom and Germany, plus 23 other European countries, for conditions including but not limited to chronic pain, intractable chemotherapy-related nausea, anxiety, insomnia, Tourette's syndrome, substance use disorder, multiple sclerosis, IBS, spinal cord treatment, lack of appetite due to HIV/AIDS, cachexia, anorexia and glaucoma.

**Caution regarding forward looking statements**

Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as "believe", "could", "should" "envisage", "estimate", "intend", "may", "plan", "potentially", "expect", "will" or the negative of those, variations or comparable expressions, including references to assumptions. These forward-looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCKZGZFGVVGFZZ

---

London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. [Terms and conditions](#), including restrictions on use and distribution apply.

---

© 2023 London Stock Exchange plc. All rights reserved.